

TheraP (ANZUP 1603) Clinical Trial Results in Lancet Oncology: Lutetium PSMA-617 is an alternative to Cabazitaxel Chemotherapy in Extended Follow-Up Study
This week the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) TheraP trial (ANZUP 1603) featured in The Lancet Oncology reported overall